Stockreport

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

ReShape Lifesciences, Inc.  (RSLS) 
US:NASDAQ Investor Relations: ir.enteromedics.com
PDF 2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Part [Read more]